PDS Biotechnology Corp(PDSB) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.64 | Insider Own | 1.73% | Shs Outstand | 105.0M | Perf Week | 22.58% |
| Market Cap | 0.16B | Forward P/E | - | EPS next Y | 35.48% | Insider Trans | - | Shs Float | 103.2M | Perf Month | 104.6% |
| Enterprise Value | 0.16B | PEG | - | EPS next Q | -0.11 | Inst Own | 19.94% | Short Float | 3.28% | Perf Quarter | 117.45% |
| Income | -0.03B | P/S | - | EPS this Y | 37.16% | Inst Trans | 4.57% | Short Ratio | 0.14 | Perf Half Y | 58.28% |
| Sales | 0.00B | P/B | - | EPS next 5Y | 32.26% | ROA | -136.65% | Short Interest | 3.39M | Perf YTD | 97.45% |
| Book/sh | -0.06 | P/C | 28.5 | EPS past 3/5Y | 19.55% 3.46% | ROE | -543.97% | 52W High | -15.08% ($1.79) | Perf Year | 62.92% |
| Cash/sh | 0.05 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 678.69% ($0.20) | Perf 3Y | -62.19% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 30.16% | Gross Margin | - | Volatility(W/M) | 16.31% 21.41% | Perf 5Y | -87.42% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.2 | Perf 10Y | -99.28% |
| Dividend Ex-Date | - | Quick Ratio | 0.57 | EPS Q/Q | 14.74% | Profit Margin | - | RSI (14) | 63.71 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.57 | Sales Q/Q | - | SMA20 | 29.93% ($1.17) | Beta | 1.3 | Target Price | $4 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/13 | SMA50 | 102.97% ($0.75) | Rel Volume | 0.62 | Prev Close | $1.3 |
| Employees | 21 | LT Debt/Eq | - | EPS/Sales Surpr. | -38.46% - | SMA200 | 84.41% ($0.82) | Avg Volume(3M) | 24.74M | Price | $1.52 |
| IPO | 2015/10/1 | Option/Short | Yes/Yes | Trades | 17215 | Volume | 15,238,327 | Change | 16.92% |
🧬 This is a US clinical-stage biotech company developing innovative immunotherapies to treat cancer and infectious diseases through its proprietary 'Versamune®' and 'Infectimune®' platforms. Its flagship program is the registration-enabling Phase 3 clinical trial of 'PDS0101' for the treatment of HPV-related head and neck cancer, driving innovation in the immuno-oncology market.
Over the past 1 year, on the higher side
15% below its 1-year high.
Traded less than usual. That is 62% of its average volume.
PDSB has weak earnings and a weak balance sheet
Review management risk carefully before investing
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +37.2% this year.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -87.4%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 19.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #324 of 594 in the industry
Based on market cap of $160M.
ALXO#321 Alx Oncology Holdings Inc $163M PER - 
CNTN#322 Canton Strategic Holdings Inc $163M PER - 
NGEN#323 NervGen Pharma Corp $161M PER - PDSB#324 PDS Biotechnology Corp $160M PER - 
MGNX#325 Macrogenics Inc $157M PER - 
FAQ
What kind of company is PDSB?
PDSB belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of PDSB?
The market cap of PDSB is approximately $160M, ranking 4,198 within its sector.
What is the 52-week high and low for PDSB?
PDSB has recorded a 52-week high of $1.79 and a low of $0.20.
